W Joost Lesterhuis

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. pmc Programmed death ligand 2 in cancer-induced immune suppression
    Esdy N Rozali
    Tumor Immunology Group, School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia
    Clin Dev Immunol 2012:656340. 2012
  2. pmc Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    J Clin Invest 121:3100-8. 2011
  3. doi Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Res 72:6102-10. 2012
  4. doi Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Immunol Immunother 60:249-60. 2011
  5. doi Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination
    Erik H J G Aarntzen
    Department of Tumor Immunology, Radboud University Nijmegen Medical Centre RUNMC, Nijmegen, The Netherlands
    Cancer Res 73:19-29. 2013
  6. doi Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
    W Joost Lesterhuis
    Department of Medical Oncology, Nijmegen Centre for Molecular Life Sciences, and Laboratory of Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 17:5725-35. 2011
  7. doi Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre RUNMC, Nijmegen, The Netherlands
    Clin Cancer Res 19:1525-33. 2013
  8. doi Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    Clin Cancer Res 18:5460-70. 2012
  9. doi Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
    Joannes F M Jacobs
    Department of Medical Oncology, Laboratory of Medical Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 16:5067-78. 2010
  10. doi Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
    Pauline Verdijk
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Science, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 15:2531-40. 2009

Collaborators

Detail Information

Publications22

  1. pmc Programmed death ligand 2 in cancer-induced immune suppression
    Esdy N Rozali
    Tumor Immunology Group, School of Medicine and Pharmacology, University of Western Australia, 4th Floor, G Block, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia
    Clin Dev Immunol 2012:656340. 2012
    ..Here, we review the literature on the immunobiology of PD-L2, particularly on its possible roles in cancer-induced immune suppression and we discuss the results of recent studies targeting PD-L2 in cancer...
  2. pmc Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    J Clin Invest 121:3100-8. 2011
    ..This dual action of platinum compounds may extend their therapeutic application in cancer patients and provides a rationale for their use in combination with immunostimulatory compounds...
  3. doi Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Res 72:6102-10. 2012
    ....
  4. doi Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Cancer Immunol Immunother 60:249-60. 2011
    ....
  5. doi Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination
    Erik H J G Aarntzen
    Department of Tumor Immunology, Radboud University Nijmegen Medical Centre RUNMC, Nijmegen, The Netherlands
    Cancer Res 73:19-29. 2013
    ..0089). In conclusion, coactivating TAA-specific CD4(+) T-helper cells with DCs pulsed with both MHC class I and II-restricted epitopes augments TAA-specific CD8(+) T-cell responses, contributing to improved clinical responses...
  6. doi Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
    W Joost Lesterhuis
    Department of Medical Oncology, Nijmegen Centre for Molecular Life Sciences, and Laboratory of Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 17:5725-35. 2011
    ....
  7. doi Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre RUNMC, Nijmegen, The Netherlands
    Clin Cancer Res 19:1525-33. 2013
    ..However, these migration rates are typically very poor. Improving the targeting of ex vivo generated DCs to LNs might increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in humans under different conditions...
  8. doi Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients
    Erik H J G Aarntzen
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    Clin Cancer Res 18:5460-70. 2012
    ..We investigated the immunologic and clinical responses to vaccination with mRNA-electroporated DC in stage III and IV melanoma patients...
  9. doi Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
    Joannes F M Jacobs
    Department of Medical Oncology, Laboratory of Medical Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 16:5067-78. 2010
    ..In this study we investigated whether transient monoclonal antibody-mediated depletion of CD25(high) regulatory T cells (Treg) is capable of enhancing the immunostimulatory efficacy of dendritic cell vaccines...
  10. doi Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
    Pauline Verdijk
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Science, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 15:2531-40. 2009
    ..In this study, we investigated the fate of DC after intradermal (i.d.) or intranodal (i.n.) administration and the consequences for the immune activating potential of DC vaccines in melanoma patients...
  11. pmc Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging
    Erik H J G Aarntzen
    Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, 6500 HB, Nijmegen, The Netherlands
    Proc Natl Acad Sci U S A 108:18396-9. 2011
    ..This technique allows for early discrimination of responding from nonresponding patients in anti-cancer vaccination and aid physicians in individualized decisionmaking...
  12. ncbi Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
    W Joost Lesterhuis
    Departments of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Anticancer Res 30:5091-7. 2010
    ..Theoretically, transfection of DCs with RNA encoding a tumor-specific antigen may induce a broader immune response as compared to the most widely used technique of peptide pulsing...
  13. ncbi Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients
    I Jolanda M de Vries
    Department of Tumor Immunology, University Medical Center St Radboud Nijmegen and Nijmegen Center for Molecular Life Sciences, Nijmegen, The Netherlands
    Clin Cancer Res 9:5091-100. 2003
    ..We have investigated the capacity of immature and mature monocyte-derived DCs pulsed with melanoma-associated peptides (gp100 and tyrosinase) to induce a primary cytotoxic T-lymphocyte response in vivo...
  14. ncbi Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines
    Pauline Verdijk
    Department of Tumorimmunology, Nijmegen Centre for Molecular Life Science, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Cancer 120:978-84. 2007
    ....
  15. pmc The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
    Jurjen Tel
    Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, The Netherlands
    Cancer Immunol Immunother 61:1101-11. 2012
    ..Our results demonstrate that platinum-based anticancer drugs adapt TLR-induced signaling in human pDCs and myeloid DCs (mDCs), thereby downgrading their immunostimulatory potential...
  16. ncbi Colitis in an alcohol-dependent woman
    Astrid Oude Lashof
    Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
    Lancet 369:2050. 2007
  17. ncbi CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma
    Willeke A M Blokx
    Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Am J Surg Pathol 31:637-41. 2007
    ..This case illustrates that molecular analysis can contribute to the sometimes-difficult differentiation between a second primary melanoma and a melanoma metastasis...
  18. doi Cancer immunotherapy--revisited
    W Joost Lesterhuis
    Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Nat Rev Drug Discov 10:591-600. 2011
    ....
  19. ncbi Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics
    Stanleyson V Hato
    Authors Affiliations Departments of Tumor Immunology and Medical Oncology, Radboud University Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, the Netherlands and National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Australia
    Clin Cancer Res 20:2831-7. 2014
    ..Clin Cancer Res; 20(11); 2831-7. ©2014 AACR. ..
  20. ncbi Phenotypical and functional characterization of clinical grade dendritic cells
    I Jolanda M de Vries
    Department of Tumot Immunology, University Medical Center St Radboud, Nijmegen, The Netherlands
    J Immunother 25:429-38. 2002
    ..In conclusion, a culture procedure was established to generate large numbers of monocyte-derived immature and mature DC that retain their morphologic, phenotypic, and functional characteristics in vitro and can be visualized in situ...
  21. ncbi PD-L2 is predominantly expressed by Th2 cells
    W Joost Lesterhuis
    University of Western Australia, Tumor Immunology Group, School of Medicine and Pharmacology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia Department of Medical Oncology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    Mol Immunol 49:1-3. 2011
    ....
  22. ncbi Comment on "drug discovery: turning the titanic"
    W Joost Lesterhuis
    School of Medicine and Pharmacology and National Centre for Asbestos Related Diseases, University of Western Australia, Harry Perkins Institute of Medical Research, 5th Floor, QQ Block, 6 Verdun Street, Nedlands, Perth, Western Australia 6009, Australia
    Sci Transl Med 6:229le2. 2014
    ..We propose that the molecular and cellular events that govern a resolving, rather than an evolving, disease may reveal new druggable pathways. ..